Showing results (51-60 of 61) with videos related to
Sort By:
Pageof 7
International Journal of Clinical Practice|October 9, 2021
Clinical-epidemiological and radiological characteristics of stroke patients: A multicentre studyRefik Kunt, Bilge Piri Çınar, Burcu Yüksel, et al.Journal of Hepatology|December 19, 2015
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapyGeorge Papatheodoridis, George Dalekos, Vana Sypsa, et al.The Lancet. Infectious Diseases|July 21, 2015
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trialChristopher Koh, Laetitia Canini, Harel Dahari, et al.Transplantation|June 9, 2022
Proceedings of the 26th Annual Virtual Congress of the International Liver Transplantation SocietyMarit Kalisvaart, Ryan Chadha, Eleonora De Martin, et al.Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|January 19, 2024
Proceedings of the 28th Annual Congress of the International Liver Transplantation SocietyJohns Shaji Mathew, Alexandra Shingina, Mohammad Qasim Khan, et al.Transplantation|May 23, 2023
Proceedings of the 27th Annual Congress of the International Liver Transplantation SocietyIsabel Campos-Varela, Ashwin Rammohan, Ryan Chadha, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 3, 2023
Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis DOlympia E Anastasiou, Florin A Caruntu, Manuela G Curescu, et al.Journal of Hepatology|January 26, 2020
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis BGeorge V Papatheodoridis, Vana Sypsa, George N Dalekos, et al.The Lancet. Infectious Diseases|March 6, 2019
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trialHeiner Wedemeyer, Cihan Yurdaydin, Svenja Hardtke, et al.Liver International : Official Journal of the International Association for the Study of the Liver|May 15, 2023
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trialKatja Dinkelborg, Julia Kahlhöfer, Petra Dörge, et al.Pageof 7